Atara Biotherapeutics Inc

NASDAQ:ATRA  
15.13
-0.63 (-4.00%)
Products, Strategic Combinations

Atara Biotherapeutics Inc And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel (Tab-Cel)

Published: 10/04/2021 11:55 GMT
Atara Biotherapeutics Inc (ATRA) - Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (tab-cel®).
Atara Biotherapeutics Inc - Will Retain Full Rights to Tab-cel(® )in Other Major Markets, Including North America, Asia Pacific, and Latin America.
Atara Biotherapeutics Inc - Under Terms of Agreement, Atara Will Receive an Upfront Payment of USD 45 Million.
Atara Biotherapeutics- Under Terms of Agreement, Atara Will Receive Approximately USD 320 Million in Additional Regulatory and Sales Milestone Payments.
Atara Biotherapeutics Inc - Tab-cel Remains On-track for European Maa Filing in November 2021.